Full profile
| Also known as | Panax quinquefolius, Cereboost |
|---|---|
| Best for | Acute working-memory support |
| Evidence grade | Grade C · Limited: early or small human trials |
| Studied dose range | 200 mg of standardized extract, single dose in the studied trials. |
| Time to effect | Acute: measured within 1–3 hours of a single dose. |
| Best form | Cereboost, standardized to roughly 10% ginsenosides. |
Evidence, honestly graded
Downgraded from B to C on 2026-07-11 under the house replication-over-recency + sponsor-dependence standard (the same basis used for Rhodiola and Panax). All three supporting acute trials (Scholey 2010, PMC2952762; Ossoukhova 2015; and White 2020, PMID 32896022, with two Naturex-employee authors) were funded by Naturex, the Cereboost developer, and the one chronic-dosing trial (Bell 2022, doi:10.1007/s00394-021-02654-5) was largely null. A single sponsor's repeated trials are self-replication, not independent replication, so the honest grade is C. This is a different species from Asian Panax ginseng; the signals should not be read across.
See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.
975 natural health products with an active licence in Health Canada's LNHPD list American Ginseng as a medicinal ingredient.
That makes American Ginseng a recognized, licensable medicinal ingredient in Canada, regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Generally well tolerated
Who should avoid it or check first
- On anticoagulants or antidiabetic medication without clinician review
- Pregnant or breastfeeding without clinician guidance
Interactions
- May interact with anticoagulants and antidiabetic medications; discuss with a clinician
Stacks well with
Use caution stacking with
- Panax Ginseng (redundant adaptogen mechanism without a clear rationale)
What to look for on a label
- Specify "American ginseng (Panax quinquefolius)," not just "ginseng," since the species and evidence base differ from Asian Panax ginseng.
- Position as acute working-memory support; chronic-use claims outrun the current evidence.
References
- Scholey 2010: Cereboost acute working-memory RCT. Single-dose Cereboost improved working-memory measures in healthy adults. PMC2952762. Educational, not a product claim.
- Ossoukhova 2015: American ginseng acute cognition trial. Further single-dose evidence for acute working-memory effects. PMID 25778987. Educational.
- Bell 2022: chronic American ginseng dosing trial. Chronic daily dosing was largely null on cognitive outcomes, the honest gap between acute and chronic evidence. doi:10.1007/s00394-021-02654-5.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-11Grade changeGrade B → Grade C
Downgraded from B to C. Acute cognitive effects appear in small trials but do not replicate consistently enough across doses and populations to hold a B.
See how American Ginseng compares on grade, dose, and goal in the Evidence Explorer.
